Services

Our services are centred around intellectual property that can be registered. We protect innovation, design, and branding across all sectors of industry, and at all stages in the supply chain.

For each IP right we offer services covering strategic advice, pre-registration searches, registrations and renewals, oppositions and dispute resolution. We handle work throughout the world, working with local colleagues in over 100 countries.

Sectors

Our attorneys specialise in one or more sectors of industry, which enables them to provide quality advice with a commercial focus.

Our patent specialists have detailed understanding of the background technology, which ensures that your patent applications are prepared with the correct scope, reducing the likelihood of challenges from third parties and objections from the patent office.

They also advise whether other forms of protection would be more appropriate. Our brand specialists work with brand managers for leading brands and their advice is commercially focussed making sure that you get the best value from your budget.

21st Jun 2022

Register here: An introduction to The European Unitary Patent & Unified Patent Court

Reddie & Grose is pleased to invite you to an online seminar which will guide you through the European Unitary Patent & Unified Patent Court (UPC).  We will provide a detailed overview of the Unitary Patent system, including the UPC, and how the new system may affect your validation and litigation strategies. The Unitary Patent […]

29th Jan 2021

NFL Seek Touchdown in Trade Mark Proceedings with XFL over Houston Roughnecks Logos

In 2001 an experimental alternative to the NFL was launched by Vince McMahon: the XFL. The XFL hosted fewer teams, promising quicker games and greater entertainment. The XFL lasted just one season before collapsing due to significant financial losses. In 2018, McMahon revived the league with a planned restart date in 2020. Fast forward to January 2021 and the picture for the XFL remains bleak, it having lasted only 5 weeks before collapsing due to financial pressures linked to COVID 19. Dwayne Johnson and his associates now own the league and another restart is scheduled for the 2022 season.

28th Jan 2021

“Means Plus Function” Language and Global Patent Specifications

Truly global patent specifications are the holy grail for applicants that file around the world. It’s easy to see why. If a specification meets the requirements of all the national patent offices in which protection is going to be sought the application will easier to prosecute and litigate locally and therefore cheaper overall.

3rd Jun 2020

Watch this SpaceX

At 1522 EDT on 30 May 2020, Doug Hurley and Bob Behnken in their Dragon capsule blasted off from Cape Canaveral and into low Earth orbit, propelled by the mighty Falcon-9 rocket.  This was the first time a private company had sent astronauts to the International Space Station, and the first time since the end of the Space Shuttle program in 2011 that anyone had travelled into space from US soil.

23rd Jan 2020

What does the US-China trade deal mean for pharmaceutical patent holders?

On Wednesday 15th January 2020, US president Donald Trump and Chinese vice-premier Liu He signed an economic and trade agreement which Mr Trump described as “the biggest deal anybody has even seen”. The deal promises to be the first phase of a larger new trade agreement between the US and China, signifying a de-escalation in their trade war – at least for now. Intellectual property (IP) was one of the main points of contention during the trade talks and thus it is perhaps unsurprising that IP matters are addressed in the first chapter. Of particular interest to those in the pharmaceutical sector will be Sections C and D of Chapter 1, which outline China’s commitment to improving protection and enforcement of pharmaceutical related patent rights. Sceptics will argue that these provisions simply represent a long overdue pledge by China to align its patent system with the US and other Western states, with no guarantee that they will actually implement or enforce the provisions of the agreement. However, in my view the deal appears to represent China’s willingness to do more to protect pharmaceutical patent rights and contains provisions that (if properly implemented and enforced) could significantly increase the value of drug related patents in China.

Saved Staff
Staff member

Remove all

Saved profiles
Call +44 (0)20 7242 0901
Call +44 (0)1223 360 350
Call +49 (0) 89 206054 267
Call +(00) 31 70 800 2162

    X

    Register for notifications
    Enter your email address here to receive our monthly bulletin of IP news and developments.

    "*" indicates required fields

    Sector*
    I confirm that I have read Reddie & Grose's privacy notice and consent to my personal information being collected*
    Please read our privacy notice.